Targeting virulence for antibacterial chemotherapy: identifying and characterising virulence factors for lead discovery

Drugs in R&D
Andrea Marra

Abstract

The antibacterial drug discovery industry is fast losing participants; at the same time it is facing the challenge of developing new antibiotics that are effective against frequently occurring and multiply resistant organisms. One intriguing approach is to target bacterial virulence, and the last decade or so has seen a focus on bacterial pathogenesis along with the development of reagents and strategies that could make this possible. Several processes utilised by a range of bacteria to cause infection may be conserved enough to make attractive targets; indeed it is known that mammalian cells can affect bacterial gene expression and vice versa. Interesting targets involving virulence include type III secretion systems, two-component signal transduction systems, quorum sensing, and biofilm formation. In order to better understand these systems and strategies, investigators have developed novel strategies of their own, involving negative selections, surrogate models of infection, and screens for gene induction and antigenicity. Inhibitors of such targets would be unlikely to adversely affect patients, be cross-resistant to existing therapies, or cause resistance themselves. It might be the case that virulence target-based therapi...Continue Reading

References

Feb 1, 1995·Trends in Microbiology·V L Miller
Jan 31, 1995·Proceedings of the National Academy of Sciences of the United States of America·M J MahanJ J Mekalanos
Mar 29, 1994·Proceedings of the National Academy of Sciences of the United States of America·A CamilliJ J Mekalanos
Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·J WangS Jin
Nov 1, 1995·Molecular Microbiology·A Camilli, J J Mekalanos
Apr 16, 1998·Molecular Microbiology·A M LoweR L Deresiewicz
Jun 10, 1998·Microbiology and Molecular Biology Reviews : MMBR·C J Hueck
Nov 24, 1998·Infection and Immunity·A PolissiD Simon
Dec 16, 1998·The Journal of Antimicrobial Chemotherapy·R G FinchG S Stewart
Sep 28, 1999·Trends in Microbiology·R D Perry
Feb 15, 2000·Molecular Microbiology·J P ThroupM K Burnham
Mar 18, 2000·Infection and Immunity·M HandfieldR C Levesque
Oct 26, 2000·Current Opinion in Microbiology·J E SheaR G Feldman
Nov 4, 2000·Expert Opinion on Investigational Drugs·M J Macielag, R Goldschmidt
Mar 21, 2001·Antimicrobial Agents and Chemotherapy·K Lewis
May 17, 2001·Antimicrobial Agents and Chemotherapy·K TatedaC Van Delden
May 22, 2001·Molecular Microbiology·G W LauD W Holden
Jun 20, 2001·Current Biology : CB·A Gauthier, B B Finlay
Jan 26, 2002·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·K TatedaK Yamaguchi
Feb 9, 2002·Current Opinion in Microbiology·Christopher Sassetti, Eric J Rubin
Feb 9, 2002·Current Opinion in Microbiology·Joan Mecsas
Apr 16, 2002·Molecular Microbiology·D Scott MerrellAndrew Camilli
May 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Hildegard EtzAndreas Meinke
Aug 2, 2002·Expert Opinion on Investigational Drugs·Lefa E Alksne
Sep 12, 2002·Expert Opinion on Therapeutic Targets·Paul Williams
Sep 27, 2002·Current Opinion in Pharmacology·Steven J Projan
Oct 2, 2002·Current Opinion in Microbiology·Steven J Projan, Philip J Youngman
Oct 16, 2002·Infection and Immunity·Jeff G LeidPaul Stoodley
Oct 31, 2002·The Journal of Antimicrobial Chemotherapy·Curtis G Gemmell, Charles W Ford
Nov 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·Michelle L ZaharikB Brett Finlay
Jan 24, 2003·Expert Opinion on Therapeutic Targets·Simone MüllerGuy R Cornelis
Feb 4, 2003·Nature Reviews. Drug Discovery·David Davies
Mar 26, 2003·Infection and Immunity·Costi D SifriStephen B Calderwood
Mar 27, 2003·Molecular Microbiology·Mark A SchembriPer Klemm

❮ Previous
Next ❯

Citations

Jun 7, 2007·Organic & Biomolecular Chemistry·Veronica Aberg, Fredrik Almqvist
Aug 20, 2010·Expert Opinion on Therapeutic Patents·Sonia Escaich
Dec 17, 2011·Nature Chemical Biology·Hiroshi AshidaChihiro Sasakawa
Mar 6, 2013·Antimicrobial Agents and Chemotherapy·Jianfang LiYuemao Shen
Jun 8, 2017·The Journal of Antibiotics·Pia UusitaloCharlotta Sundin
Jan 23, 2018·Frontiers in Immunology·Olivia I Coleman, Dirk Haller
Apr 29, 2009·Journal of Proteome Research·Sung-Ha ParkKwang-Jun Lee
Oct 25, 2008·Journal of Medicinal Chemistry·Toni KlineSamuel I Miller
Jul 4, 2009·ACS Chemical Biology·Terence I MoyFrederick M Ausubel
Sep 14, 2011·The Journal of Physical Chemistry. B·Ting ShiJian Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Expert Review of Anti-infective Therapy
Andrea Marra
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Ryutaro Utsumi, Masayuki Igarashi
Current Opinion in Pharmacology
Jie Zhu, Gunnar F Kaufmann
Molekuliarnaia genetika, mikrobiologiia i virusologiia
T S Il'inaA L Gintsburg
© 2022 Meta ULC. All rights reserved